Vericel Corporation engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee. Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal. NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-th thickness.